Brivanib clinical trials
Also written BMS-582664.
How each study uses brivanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 7
Bristol-Myers Squibb (15) · Zai Lab (Shanghai) Co., Ltd. (2) · Gynecologic Oncology Group (2) · NCIC Clinical Trials Group (1) · Abramson Cancer Center at Penn Medicine (1) · M.D. Anderson Cancer Center (1) · Chongqing University Cancer Hospital (1) · Hunan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Irinotecan (2) · Sorafenib (1) · Cetuximab (1) · Fluorouracil (1) · Leucovorin (1) · Tebotelimab (1) · Niraparib (1) · Toripalimab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses brivanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsTerminatedPhase 1/2Zai Lab (Shanghai) Co., Ltd.NCT04212221Written as MGD013 in combination with Brivanib Alaninate
- A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerCompletedPhase 2Bristol-Myers SquibbNCT00355238Written as brivanib (active)
- Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal CancerCompletedPhase 3NCIC Clinical Trials GroupNCT00640471Written as brivanib alaninate
- Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical CancerStatus unknownPhase 2Chongqing University Cancer HospitalNCT04395612Written as niraparib combined with brivanib
- Brivanib Metastatic Renal Cell CarcinomaTerminatedPhase 2Abramson Cancer Center at Penn MedicineNCT01253668Written as Brivanib alaninate
- Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGFTerminatedPhase 2M.D. Anderson Cancer CenterNCT01367275Written as Brivanib
- Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCCCompletedPhase 3Bristol-Myers SquibbNCT00908752Written as Brivanib
- Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib TreatmentCompletedPhase 3Bristol-Myers SquibbNCT00825955Written as Brivanib
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedPhase 2Zai Lab (Shanghai) Co., Ltd.NCT03516071Written as Brivanib 800 mg, QD
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownPhase 1Hunan Cancer HospitalNCT03895788Written as Brivanib
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical CancerCompletedPhase 2Gynecologic Oncology GroupNCT01267253Written as Brivanib Alaninate
- Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedPhase 2Gynecologic Oncology GroupNCT00888173Written as Brivanib Alaninate
- First Line Hepato Cellular Carcinoma (HCC)CompletedPhase 3Bristol-Myers SquibbNCT00858871Written as Brivanib
- Phase I/II Combination With Irinotecan- ErbituxCompletedPhase 1/2Bristol-Myers SquibbNCT00594984Written as Brivanib
- Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTerminatedPhase 3Bristol-Myers SquibbNCT01108705Written as Brivanib
- Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedPhase 2Bristol-Myers SquibbNCT00633789Written as brivanib
- Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)CompletedPhase 1Bristol-Myers SquibbNCT01046864Written as Brivanib
- Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)CompletedPhase 1Bristol-Myers SquibbNCT01540461Written as Brivanib
- A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)CompletedPhase 1Bristol-Myers SquibbNCT00437437Written as Brivanib
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver DysfunctionCompletedPhase 1Bristol-Myers SquibbNCT00437424Written as Brivanib
See all 24 studies that test brivanib →
Given beside what is tested · 1 — brivanib is usual care or a partner of the new treatment
Codes
What other systems call brivanib · ClinicalTrials.gg INT004906
- MeSH (NLM) C509922brivanibOne source NLM
- UNII (FDA) DDU33B674IBRIVANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27075503brivanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C67040BrivanibOne source FDA
- DrugBank DB11958One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509922 | brivanib | One source NLM |
| UNII (FDA) | DDU33B674I | BRIVANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27075503 | brivanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C67040 | Brivanib | One source FDA |
| DrugBank | DB11958 | — | One source Wikidata |
Also registered as brivanib alaninate (UNII U2Y5OFN795).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.